Scienza e Tecnologia
Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop its Digital Sedation™ through Virtual Reality
Founded in 2017, Oncomfort is a Belgian scale-up specialized in Digital Sedation ™ , a completely new method for relieving patients' pain and anxiety through treatment with clinically proven sessions of therapeutic Virtual Reality. Since the launch of the Sedakit™ for Digital Sedation ™ in Benelux and France in June 2019 , over 30,000 patients have been treated and have had their pain and anxiety relieved before, during, and after interventions in many clinical fields such as anesthesia, oncology, interventional radiology and cardiology, as well as pediatrics.
Oncomfort has raised no less than €10 million in a Series A funding round. It plans to use this investment to develop its Digital Sedation ™ solution and accelerate its international expansion on the European and American markets. The investment round was realized with two leading institutional investors: the Swiss Debiopharm, and the French Crédit Mutuel Innovation (CMI). The investment includes continuing support from Wallonia Innovation and Growth (W.IN.G) and the existing investors. Both institutional investors will join Oncomfort's newly composed Board of Directors.
" " says Mario Huyghe , CEO of Oncomfort. " Digital Sedation ™ ."
" ," explained Thierry Mauvernay, President of Debiopharm.
continued Karine Lignel , CEO of Crédit Mutuel Innovation.
" " said Tanja Dowe , CEO of Debiopharm Innovation Fund.
" explained Delphine Cardi , Director of Participations, and Tanguy Besson , Associate at Crédit Mutuel Innovation.
concluded Colin Loyens , Investment Manager.
Oncomfort, founded in 2017 and headquartered in Wavre near Brussels ( Belgium ), combines Virtual Reality capabilities and knowledge on clinical hypnosis into an innovative medical solution for digital sedation. Co-founders Diane Jooris , Gérald de Patoul, Mario Huyghe , and Julien Tesse built a co-creative team that successfully brings to market medical CE-approved applications for digital sedation as well as anxiety and pain management. Both nationally and internationally, Oncomfort has received multiple awards in the fields of clinical application, innovation, and entrepreneurship.
For more information, please visit www.oncomfort.com.
Or find us on LinkedIn.
Press contact
Laurence de Crombrugghe
laurence@oncomfort.com, +32 (0)478 39 47 50
Leslie Buyle for Oncomfort
Leslie.buyle@ketchum.com, +32 (0)498 67 46 15
Debiopharm develops, manufactures, and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. Through our digital health investments, we provide funding and strategic guidance for companies with an ambition to improve the patient journey and re-imagine how clinical trials are conducted. Our growing portfolio company achievements include 10 FDA clearances, 13 CE marks, 2 IPOs, and 4 trade exits. Since 2008, we have invested over USD 120 million , typically leading the investment rounds of our 16 portfolio companies.
For more information, please visit https://www.debiopharm.com/digital-health/.
Or follow us on Twitter via @debiopharmfund.
Press contact
Dawn Haughton
dawn.haughton@debiopharm.com, +41 (0)21 321 01 11
Crédit Mutuel Innovation is the venture capital subsidiary of Crédit Mutuel Equity (€ 3.0 billion in capital), a member of Crédit Mutuel Alliance Fédérale. Its objective is to invest in companies developing promising technologies. Crédit Mutuel Innovation selects companies with strong growth potential in dynamic sectors such as information technology, telecommunications, electronics, life sciences, new materials and environment. For more than 15 years, Crédit Mutuel Innovation has invested - and often reinvests - its own capital to support innovative companies to their market. Crédit Mutuel Innovation's policy is to provide long-term equity support to innovative startups to streamline their chances of success.
For more information, please visit www.creditmutuelequity.com.
Innovation contact
Delphine Cardi , Investment Director
delphine.cardi@creditmutuel.fr, +33 (0)7 87 13 92 97
Tanguy Besson , Associate
tanguy.besson@creditmutuel.fr, +33 (0)6 44 26 05 86
Press contact
Véronique Richez-Lerouge
v.richez-lerouge@reso-media.com, +33 (0)6 14 63 90 00